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Introduction {#sec005}
============

More than half of patients receiving short-term, high-dose glucocorticoid therapy for conditions like COPD exacerbations, cord compression or post-transplantation experience hyperglycemia \[[@pone.0231190.ref001]\]. This may reflect exacerbation of type 2 diabetes mellitus (T2DM) \[[@pone.0231190.ref002]\] or can occur in those undiagnosed with diabetes. The hyperglycemia mechanism has been attributed to glucocorticoid-induced insulin resistance and increased hepatic glucose output \[[@pone.0231190.ref003]\].

Effects of high-dose glucocorticoids on beta-cell function have not been studied extensively. Several studies in healthy men receiving glucocorticoids showed beta-cell function impairment with C-peptide secretion decreased after a short course of high-dose glucocorticoids \[[@pone.0231190.ref004], [@pone.0231190.ref005]\]. No similar studies have been done in people with T2DM. Thus, it is unknown whether and to what extent beta-cell function changes seen in healthy subjects can occur in those with T2DM exposed to short-term high-dose glucocorticoids.

In this study, we aimed to evaluate the effect of a short course of high-dose glucocorticoids on beta-cell function and insulin resistance in adults with new T2DM and assess whether this differs from healthy adults. We chose to use prednisone 40 mg to mirror previous studies in healthy volunteers. \[[@pone.0231190.ref004]\] This dose also reflects very common short usage of prednisone for intercurrent respiratory infections.

Materials and methods {#sec006}
=====================

Study subjects {#sec007}
--------------

This study used a convenience sample of consecutive five healthy adults and five adults with recent onset T2DM. The study was approved by the institutional review board at John H. Stroger Jr Hospital of Cook County. All participants signed written informed consent before participation.

Eligible subjects with T2DM were between 18 and 50 years of age, diagnosed within 1 year of recruitment, HbA~1c~ ≤75 mmol/mol (9.0%), used only metformin therapy, with BMI of 24--35 kg/m^2^. Exclusion criteria included estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m^2^, glucocorticoid use within six months of recruitment, diabetes therapy other than metformin, shift work, baseline fasting plasma glucose (FPG) ≥13.9 mmol/L, or signs or symptoms of infection.

Eligible healthy control subjects were between 18 and 50 years of age, in good physical health per medical history, physical examination, and screening blood tests, were normoglycemic (FPG \<5.55 mmol/L), with BMI of 22--28 kg/m^2^. Exclusion criteria included presence of any chronic disease or any medication use, a first-degree relative with T2DM, history of smoking, glucocorticoids use, shift work, or recent changes in weight or physical activity.

Study protocol {#sec008}
--------------

All subjects (5 subjects with T2DM and 5 healthy subjects) had vitals checked, underwent a physical exam and had comprehensive metabolic panel, lipid panel, and HbA~1c~ drawn. After a 10-hour overnight fast, a 75-g oral glucose tolerance test (OGTT) was done and plasma glucose, C-peptide, and insulin were measured at 0, 30 and 60 minutes. After the OGTT, prednisone 40 mg was administered. Study subjects were given prednisone 40 mg to take at 8am the following day. On the third day, all patients returned to be examined and receive the third dose of prednisone 40 mg. Two hours later, another OGTT and blood samples were collected similarly to the first day.

Safety protocol {#sec009}
---------------

On the first day, all subjects were trained on self-monitoring of capillary glucose and provided glucometers, test strips, lancets, and ketostix. Participants were instructed to check blood glucose levels fasting, pre-prandial (x3 meals), and at bedtime from study day one and up to 2 days after the second visit. Study coordinator followed-up daily on the blood glucose levels. If blood glucose levels rose above 16.67 mmol/L for more than 2 measurements, subject was withdrawn and blood glucose levels followed by study personnel until it was less than 16.67 mmol/L.

Outcomes and measures {#sec010}
---------------------

The primary outcome was beta-cell function and insulin resistance relative changes within and between groups after 3 day exposure of prednisone 40 mg/daily. Beta-cell function measures included OGTT-generated areas under the curve (AUC) of C-peptide levels (AUC~C-PEP~) measured before and after prednisone exposure, as well as the AUC of glucose and insulin levels, an insulinogenic index (IGI) \[[@pone.0231190.ref006]\], homeostasis model assessment of beta-cell function (HOMA-%B) and homeostasis model assessment of insulin resistance (HOMA-IR) \[[@pone.0231190.ref007]\].

Statistical analysis {#sec011}
--------------------

We based the sample size calculation on the glucocorticoid-induced changes in fasting C-peptide levels found in healthy volunteers in previous studies \[[@pone.0231190.ref004]\]. We estimated a sample size of 5 participants in each group to provide 80% power to detect a change of 1 unit (nmol/L) between baseline C-peptide and post-glucocorticoid exposure values with a SD of 0.55 and significance level of 0.05.

The AUCs for glucose and C-peptide were calculated using the trapezoidal rule. The IGI, an indicator of early insulin response, was calculated as the ratio of insulin level to glucose response at 0 and 30 minutes (ΔI~30pmol/L~/ΔG~30mmol/L~) \[[@pone.0231190.ref006]\]. The HOMA-%B and HOMA-IR were calculated as described by Matthews et al using updated online tool \[[@pone.0231190.ref007]\].

Results were expressed in median and interquartile ranges (IQR) and statistical significance was evaluated using independent samples Mann Whitney U test (intergroup comparisons) and related samples Wilcoxon signed rank test (intragroup comparisons).

Results {#sec012}
=======

All 10 subjects recruited completed the 3-day prednisone course and the pre- and post-OGTT. Of the five patients with diabetes, three were treated with metformin before and during the study and two were without diabetes medications. Baseline characteristics differed for age, body weight, BMI and blood pressure (systolic and diastolic) between the groups ([Table 1](#pone.0231190.t001){ref-type="table"}). As expected, they also differed in HbA1c.

10.1371/journal.pone.0231190.t001

###### Characteristics and outcomes.

![](pone.0231190.t001){#pone.0231190.t001g}

  ---------------------------------------------------------------- -------------------------------- ------------------------------------------------------------ ---------------------------- ----------------------
  **Baseline Characteristics**                                                                                                                                                                
  **Group**                                                        **Subjects with T2DM (n = 5)**   **Healthy Subjects (n = 5)**                                                              
  Age (years)[\*](#t001fn002){ref-type="table-fn"}                 46.0 (36.5--48.5)                29.0 (25.5--31.0)                                                                         
  Male gender (n)                                                  4 (80%)                          2 (40%)                                                                                   
  Weight (kg)[\*](#t001fn002){ref-type="table-fn"}                 86.9 (74.9--98.0)                59.1 (56.0--75.7)                                                                         
  Height (cm)                                                      164.0 (158.5--172.7)             164.0 (159.5--170.9)                                                                      
  Body mass index (kg/m^2^)[\*](#t001fn002){ref-type="table-fn"}   32.3 (28.9--34.0)                22.1 (22.0--25.9)                                                                         
  Waist Circumference (cm)                                         107.0 (100.3--116.5)             78.5 (75.8--88.0)                                                                         
  Systolic BP (mm Hg)[\*](#t001fn002){ref-type="table-fn"}         128.0 (114.5--134.0)             109.0 (105.0--115.5)                                                                      
  Diastolic BP (mm Hg)[\*](#t001fn002){ref-type="table-fn"}        87.0 (73.5--94.0)                71.0 (60.5--77.5)                                                                         
  HbA1c (mmol/mol)                                                 55 (49--58)                      29 (27--32)                                                                               
  HbA1c (%)[\*](#t001fn002){ref-type="table-fn"}                   7.2 (6.6--7.5)                   4.8 (4.6--5.1)                                                                            
  T2DM Duration (months)                                           4.0 (1.0--9.5)                   NA                                                                                        
  eGFR (mL/min/1.73 m^2^)                                          106.0 (91.0--107.0)              101.0 (93.0--124.5)                                                                       
  **Outcomes after 3 days of prednisone administration**                                                                                                                                      
  **Group**                                                        **Subjects with T2DM (n = 5)**   **Healthy Subjects (n = 5)**                                                              
  Baseline                                                         After 3 days of prednisone       Baseline                                                     After 3 days of prednisone   
  FPG (mmol/L)[\*](#t001fn002){ref-type="table-fn"}                5.9 (5.3--6.4)                   7.0 (6.6--7.2)                                               4.8 (4.4--5.1)               5.2 (4.6--5.9)
  AUC Glucose (mmol/L/min)                                         616.8 (472.1--674.5)             734.1 (639.8--808.8)[^&^](#t001fn003){ref-type="table-fn"}   366.5 (333.5--459.1)         409.7 (373.9--439.8)
  AUC C-Peptide (nmol/L/min)                                       129.5 (52.3--160.7)              80.1 (49.1--97.8)                                            94.5 (62.2--140.6)           108.0 (83.8--164.7)
  AUC Insulin (nmol/L/min)                                         31.6 (8.5--49.4)                 13.7 (8.2--21.2)                                             23.2 (18.4--39.9)            17.9 (16.0--42.1)
  Insulinogenic Index                                              66.7 (47.4--132.1)               24.5 (15.0--37.2)[^&^](#t001fn003){ref-type="table-fn"}      258.0 (109.9--452.4)         164.3 (95.9--438.4)
  HOMA-IR                                                          1.57 (0.91--4.12)                1.35 (1.04--1.59)                                            0.65 (0.54--1.1)             0.71 (0.50--1.03)
  HOMA-%B                                                          89.9 (79.4--158.1)               58.0 (49.5--64.5)[^&^](#t001fn003){ref-type="table-fn"}      84.0 (68.5--114.3)           72.9 (54.7--89.2)
  ---------------------------------------------------------------- -------------------------------- ------------------------------------------------------------ ---------------------------- ----------------------

Data presented as mean ± SD or median (IQR) or absolute value (percentage). FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; eGFR, estimated glomerular filtration rate.

\* = p ≤0.05 between groups.

^&^ = p≤ 0.05 within groups

The AUCs (Glc, C-peptide and insulin), IGI and HOMA-%B and -IR are shown in [Table 1](#pone.0231190.t001){ref-type="table"}. In healthy subjects, there were no statistically significant differences between the pre- and post-prednisone values for any of the variables above. In the subjects with T2DM, the pre- and post-prednisone values were statistically significant for the rise in AUC Glc, decrease in IGI and HOMA-%B. There was also a decrease in the AUC for insulin and C-peptide but it was not significant (both p = 0.08).

The relative percent changes between groups for the AUCs, IGI and HOMA-%B and -IR are shown in [Fig 1](#pone.0231190.g001){ref-type="fig"}. In the T2DM group, the increase in AUC Glc was significantly higher (p = 0.016) and the IGI decreased significantly more (69.2% vs 34.3%, p = 0.008). The AUC C-peptide percent decrease more in T2DM group but did not reach significance (p = 0.056). Other variables were not significantly different. The safety glucose monitoring only registered 1 value above 16.67 mmol/L (17.5 mmol/L), in a subject with T2DM, and that subject returned to lower values in the next measurement.

![Comparisons of median percent changes of glycemic and beta cell parameters from baseline to after prednisone exposure between the healthy and T2DM groups.](pone.0231190.g001){#pone.0231190.g001}

Discussion {#sec013}
==========

In this study, after the administration of prednisone 40 mg/daily for three days, there was decreased beta-cell insulin secretion in subjects with T2DM. This was evidenced by a significant drop in the IGI and HOMA-%B, and near significant decrease in the insulin and C-peptide AUC. The healthy controls did not have significant decreases in beta-cell insulin secretion parameters after prednisone exposures. The relative percent decrease in insulin secretion was also significantly higher in T2DM in comparison to healthy controls. The expected rise in insulin resistance \[[@pone.0231190.ref008]\] did not occur in either group.

Subjects with T2DM in this study showed vulnerability to short exposure of high-dose glucocorticoids. The increase in glucose AUC was explained by an acute decrease in beta-cell function, mainly related to decreased beta-cell capacity to react to a hyperglycemic stimulus shown by an almost 70% drop in IGI in subjects withT2DM. In healthy subjects on the second day after exposure to one day of prednisone, insulin secretion recovered \[[@pone.0231190.ref004]\]. Such a recovery can be postulated in our healthy subjects who did not show significant insulin secretion decline after 3 days of prednisone exposure. The acute beta-cell impairment by glucocorticoids in healthy subjects has been shown to be temporary and reversible \[[@pone.0231190.ref004]\]. The causation may be multifactorial as has been shown in experimental models. In normal mouse islet cells, a dexamethasone treatment decreased insulin secretion through a lower efficacy of cytoplasmic calcium on the exocytosis process in the beta cells. \[[@pone.0231190.ref009]\]. Additionally, glucocorticoids influence the expression of G proteins in different tissues and this may have a role in insulin secretion in the beta cells. \[[@pone.0231190.ref009]\]. In none of these studies were diabetes models used.

In this study, subjects with T2DM were still affected up to the third day as demonstrated by the drop in IGI and HOMA-%B. Based on our study, one can speculate that subjects with T2DM have an increased beta-cell impairment and reduced ability to recover after glucocorticoid exposure. Unknown are the duration of beta-cell impairment and whether insulin resistance will increase in multi-day exposure to glucocorticoids, as has been shown in healthy men \[[@pone.0231190.ref010]\].

This study had several limitations. First, it included a small number of participants in each group, which may explain why compared to previous studies done on healthy patients \[[@pone.0231190.ref003], [@pone.0231190.ref004]\], we did not see a significant difference in their beta-cell function parameters. However, as stated above, the beta-cell emergent response is short-lived in healthy individuals and recovered at the third day. Second, the two groups had an age mismatch. We had limited ability to find younger patients with T2DM who did not have the exclusion criteria of BMI \>35.0 kg/m^2^, likely due to the association of obesity to the pathophysiology of T2DM, especially in younger people. We consider this a reasonable tradeoff, as higher BMI values may affect the insulin resistance value more than older ages, obscuring a possible effect of the glucocorticoids.

In conclusion, these results show that a short course of high-dose glucocorticoids in those with T2DM leads to hyperglycemia due to a significant decrease in insulin secretion. Further studies with larger cohorts and longer exposure to glucocorticoids are needed to clarify what pathophysiological mechanisms operate over time in these patients.
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5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Although the authors addressed a clinical issue about the effect of prednisone on beta-cell function between T2DM patients and healthy people, the sample size was too small to support the conclusion, and the mismatch of age and gender lead to large sample bias. To the reviewer\'s opinion, more rigorous experiments and data were needed to confirm the conclusions.

We agree with the concerns of Reviewer \#1. The size used was based on our sample calculation for the limited outcomes measured. Despite these concerns there were significant differences between the two groups. To avoid type 1 error, there is a need to confirm the study findings with bigger and better matched groups. We indicated this in the limitations (page 8, line 159-161) and in the conclusion (page 9, line 172).

Reviewer \#2: Shah and colleagues drew a preliminary but interesting study concluding high-dose prednisone resulting in suppressed insulin secretion rather than increasing insulin resistance. The conclusion seems result-based, but some concerns should be noted before its publication.

1\. How did the author confirm the diagnosis of type 2 diabetes? As this is a very small sample trial, the representation of the study is exclusively important (authors may wish to add differentiating information like auto-antibodies, baseline 8 am cortisol and other MODY phenotypes).

We confirmed the diagnosis of type 2 diabetes using the standard criteria of A1c above 6.5% (present in 5/5 cases and 0/5 controls). In addition, our patients underwent OGTT, which showed criteria for diagnosis of DM2 in 4/5 cases and 0/5 controls. All patients had normal C-peptide production levels at baseline time for OGTT, which would rule out significant autoimmune diabetes as the cause of hyperglycemia. MODY phenotypes were not likely since those with diabetes were relatively well-controlled and none were treated with sulfonylurea medications.

2\. The therapeutic regimens need to be provided including a daily dose of metformin. If there is any dose change of metformin during the trial, it should be reported.

Of the five patients with diabetes, three were treated with metformin before and during the study and two were without diabetes medications (added to pages 5-6, lines 105-107); there was no change to any doses of medications. Patients were informed of the importance of continuing all their medications during the time of the prednisone administration.

 

3\. Are there any other safety issues reported in the trial, such as hypertension, insomnia, etc?

No other safety issues were reported per patient after interview with research assistant on day of 3rd dose administration.

4\. The reduction of AUC C-peptide and AUC Insulin is not totally in line. Please explain.

The reduction of AUC of both C-peptide and insulin were in the same direction for the group of subjects with diabetes. For the healthy subjects, the explanation for discordant direction of the insulin and C-peptide may lie in the outlier values of two patients in whom both the insulin and C-peptide went up but only minimally.

5\. The authors may wish to provide some clinical interpretations in steroid usage, especially the clinical context of a three-day prescription of 40mg/d prednisone.

The dose selected was similar to that used in study of healthy volunteers. This is also the dose recommended for short courses of steroids in case of COPD or asthma exacerbation. This explanation is included in the introduction (page 3, lines 44-45).

6\. The authors may also wish to discuss the underlying pathophysiological mechanism of the study result in more detail.

Discussion of the mechanisms causing the beta cell impairment was amplified (page 8, lines 145-149).

7\. This trial does not include a dose gradient of prednisone, which is also a limitation needing stated.

The few data available show that dose ranges from 30-75 mg/day do not seem to cause different effects in patients without diabetes mellitus. See page 3, lines 42-45 for rationale of dosing.

8\. I think \"emergent response of beta-cell function\" rather than \"short-short effects\" may more fit the study context.

Wording was changed on page 9, line 162 to incorporate this suggestion.

9\. Please note some typos like OGGT in the manuscript.

Corrections made.

 

Reviewer \#3: In their manuscript entitled "Effect of short-term prednisone on beta-cell function in subjects with type 2 diabetes mellitus and healthy subjects,\" Shah and colleagues report that that a short course of high-dose glucocorticoids in those with T2DM leads to a significant decrease in insulin secretion. However, the healthy controls did not have significant decreases in beta-cell insulin secretion parameters after prednisone exposures. The authors believe that subjects with T2DM have an increased beta-cell impairment and reduced ability to recover after glucocorticoid exposure.

Overall, the authors report very interesting results; however, a few issues do require attention in my opinion.

1\. In fact, many studies have demonstrated that glucocorticoids treatment may lead to insulin resistance, increased hepatic gluconeogenesis and hyperglycemia in animals and human. Of note, these effects of glucocorticoids are dependent on long term treatment (for example, 2 weeks or 3 weeks). However, in the present study, human subjects were treated with glucocorticoid for 3 days. Thus, the authors just observed short effects of glucocorticoid treatment. These data are interesting. However, when the authors make conclusion, they should be more objective and fair. In my opinion, they should conclude that short-term glucocorticoid treatment may impair insulin secretion and beta cell in patients with type 2 diabetes. They cannot deny the long-term effects of glucocorticoids on insulin resistance and hepatic gluconeogenesis.

We agree with reviewer, that the long term effect of the glucocorticoids in healthy volunteers has been shown multiple times. Our study is the first to evaluate the response in patients with type 2 diabetes, although only for the initial 72 hours of administration. We agree that studies still need to be done for effects over the long term. Edits have been made on page 9, lines 170-172 to reflect this.

2\. The mechanism of this study is completely unclear, and the mechanism of how glucocorticoid affects the decrease of insulin secretion by beta cells in diabetic patients is unclear. The authors should discuss this issue, based on the previous literatures

Discussion of the mechanisms causing the beta cell impairment was amplified (page 8, lines 145-149).

3\. The number of participants is not enough. The author also mentioned this point and acknowledged this weakness.

The size used was based on our sample calculation for the limited outcomes measured. Despite these concerns there were significant differences between the two groups. To avoid type 1 error, there is a need to confirm the study findings with bigger and better matched groups. We indicated this in the limitations (page 8, line 159-161) and in the conclusion (page 9, line 172).
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